New perspectives for hexavalent vaccines
- PMID: 28676382
- DOI: 10.1016/j.vaccine.2017.06.063
New perspectives for hexavalent vaccines
Abstract
With the increase in the number of routine vaccinations the development of pentavalent and hexavalent combination vaccines fitting the routine vaccination schedules became a necessity. In this respect, Europe has taken the lead in comparison with other world regions, and routine vaccination with pentavalent and hexavalent combinations including DTPa, Hib, HepB and IPV has been on European vaccination programs for >15years. Since the marketing authorization of Hexavac® and Infanrix Hexa® in 2000, immunization schedules in most European countries have included hexavalent vaccines. In the last years, two new hexavalent vaccines have been licensed and commercialized worldwide. This paper presents a review of the pharmaceutical profiles of the three hexavalent vaccines currently available. In addition, we aim to review safety, co-administration, tolerability and other practical concerns of their use.
Keywords: Combination vaccines; Hexavac; Hexavalent vaccines; Hexyon; Infanrix Hexa; Vaccines; Vaxelis.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination.Paediatr Drugs. 2019 Oct;21(5):397-408. doi: 10.1007/s40272-019-00353-7. Paediatr Drugs. 2019. PMID: 31444785 Free PMC article. Review.
-
Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).BioDrugs. 2010 Oct 1;24(5):299-302. doi: 10.2165/11206690-000000000-00000. BioDrugs. 2010. PMID: 20795752 Review.
-
Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.Lancet Infect Dis. 2018 Jul;18(7):749-757. doi: 10.1016/S1473-3099(18)30166-X. Epub 2018 May 8. Lancet Infect Dis. 2018. PMID: 29752131
-
DTaP5-HB-IPV-Hib Vaccine (Vaxelis®): A Review of its Use in Primary and Booster Vaccination.Paediatr Drugs. 2017 Feb;19(1):69-80. doi: 10.1007/s40272-016-0208-y. Paediatr Drugs. 2017. PMID: 28035545 Review.
-
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.Hum Vaccin Immunother. 2014;10(10):2795-8. doi: 10.4161/21645515.2014.970494. Hum Vaccin Immunother. 2014. PMID: 25483640 Free PMC article.
Cited by
-
Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants.Clin Exp Pediatr. 2021 Dec;64(12):602-607. doi: 10.3345/cep.2021.00507. Epub 2021 Jun 8. Clin Exp Pediatr. 2021. PMID: 34098627 Free PMC article.
-
DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination.Paediatr Drugs. 2019 Oct;21(5):397-408. doi: 10.1007/s40272-019-00353-7. Paediatr Drugs. 2019. PMID: 31444785 Free PMC article. Review.
-
Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries.Hum Vaccin Immunother. 2023 Dec 31;19(1):2202124. doi: 10.1080/21645515.2023.2202124. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37102330 Free PMC article.
-
Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in India.Vaccine X. 2022 Jan 10;10:100137. doi: 10.1016/j.jvacx.2021.100137. eCollection 2022 Apr. Vaccine X. 2022. PMID: 35462885 Free PMC article.
-
Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology.Ital J Pediatr. 2019 Nov 19;45(1):145. doi: 10.1186/s13052-019-0742-7. Ital J Pediatr. 2019. PMID: 31744514 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
